Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative organism of COVID-19. Since this disease is considered new and does not have an approved curative protocol, many researchers have tackled the possible options for COVID-19 prevention and therapeutic approaches. We address...

Descripción completa

Detalles Bibliográficos
Autores principales: AbouSamra, Mona Mahmoud, Mansy, Soheir Said
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675919/
https://www.ncbi.nlm.nih.gov/pubmed/36415639
http://dx.doi.org/10.34172/apb.2022.067
_version_ 1784833476149641216
author AbouSamra, Mona Mahmoud
Mansy, Soheir Said
author_facet AbouSamra, Mona Mahmoud
Mansy, Soheir Said
author_sort AbouSamra, Mona Mahmoud
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative organism of COVID-19. Since this disease is considered new and does not have an approved curative protocol, many researchers have tackled the possible options for COVID-19 prevention and therapeutic approaches. We address herein the phenomena of cytokine storm (the main cause of death) associating with the late stage of COVID19. Cytokine storm is undertaken in an attempt to provide information about its possible underlying causes, and to clarify some points that can be of value in guiding treatment practices for a clinical trial.
format Online
Article
Text
id pubmed-9675919
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Tabriz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-96759192022-11-21 Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial AbouSamra, Mona Mahmoud Mansy, Soheir Said Adv Pharm Bull Editorial Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative organism of COVID-19. Since this disease is considered new and does not have an approved curative protocol, many researchers have tackled the possible options for COVID-19 prevention and therapeutic approaches. We address herein the phenomena of cytokine storm (the main cause of death) associating with the late stage of COVID19. Cytokine storm is undertaken in an attempt to provide information about its possible underlying causes, and to clarify some points that can be of value in guiding treatment practices for a clinical trial. Tabriz University of Medical Sciences 2022-08 2021-10-06 /pmc/articles/PMC9675919/ /pubmed/36415639 http://dx.doi.org/10.34172/apb.2022.067 Text en ©2022 The Authors. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
spellingShingle Editorial
AbouSamra, Mona Mahmoud
Mansy, Soheir Said
Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial
title Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial
title_full Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial
title_fullStr Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial
title_full_unstemmed Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial
title_short Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial
title_sort promising adjunct medicines in the protocol of covid-19 clinical trial
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675919/
https://www.ncbi.nlm.nih.gov/pubmed/36415639
http://dx.doi.org/10.34172/apb.2022.067
work_keys_str_mv AT abousamramonamahmoud promisingadjunctmedicinesintheprotocolofcovid19clinicaltrial
AT mansysoheirsaid promisingadjunctmedicinesintheprotocolofcovid19clinicaltrial

Ejemplares similares